PL450139A1 - 4-N-furfurylocytozyna i kompozycja ją zawierająca do zastosowań medycznych - Google Patents

4-N-furfurylocytozyna i kompozycja ją zawierająca do zastosowań medycznych

Info

Publication number
PL450139A1
PL450139A1 PL450139A PL45013924A PL450139A1 PL 450139 A1 PL450139 A1 PL 450139A1 PL 450139 A PL450139 A PL 450139A PL 45013924 A PL45013924 A PL 45013924A PL 450139 A1 PL450139 A1 PL 450139A1
Authority
PL
Poland
Prior art keywords
furfurylcytosine
compositions containing
medical use
medicament
prevention
Prior art date
Application number
PL450139A
Other languages
English (en)
Inventor
Eliza Wyszko
Agnieszka Fedoruk-Wyszomirska
Paweł Pawelczak
Dorota Gurda-Woźna
Małgorzata GIEL-PIETRASZUK
Marta Orlicka-Płocka
Original Assignee
Instytut Chemii Bioorganicznej Polskiej Akademii Nauk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Chemii Bioorganicznej Polskiej Akademii Nauk filed Critical Instytut Chemii Bioorganicznej Polskiej Akademii Nauk
Priority to PL450139A priority Critical patent/PL450139A1/pl
Publication of PL450139A1 publication Critical patent/PL450139A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem wynalazku jest 4-N-furfurylocytozyna o wzorze 1 i kompozycja farmaceutyczna zawierająca 4-N-furfurylocytozynę do zastosowania jako lek, w szczególności do zastosowania w zapobieganiu i/lub leczeniu choroby neurodegeneracyjnej.
PL450139A 2024-10-25 2024-10-25 4-N-furfurylocytozyna i kompozycja ją zawierająca do zastosowań medycznych PL450139A1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL450139A PL450139A1 (pl) 2024-10-25 2024-10-25 4-N-furfurylocytozyna i kompozycja ją zawierająca do zastosowań medycznych

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL450139A PL450139A1 (pl) 2024-10-25 2024-10-25 4-N-furfurylocytozyna i kompozycja ją zawierająca do zastosowań medycznych

Publications (1)

Publication Number Publication Date
PL450139A1 true PL450139A1 (pl) 2026-04-27

Family

ID=99547518

Family Applications (1)

Application Number Title Priority Date Filing Date
PL450139A PL450139A1 (pl) 2024-10-25 2024-10-25 4-N-furfurylocytozyna i kompozycja ją zawierająca do zastosowań medycznych

Country Status (1)

Country Link
PL (1) PL450139A1 (pl)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009349A2 (en) * 2003-07-22 2005-02-03 Supergen, Inc. Composition and method for treating neurological disorders
WO2009067035A2 (en) * 2007-11-25 2009-05-28 Instytut Chemii Bioorganicznej Pan Method of obtaining of 4-n-furfurylcytosine and/or its derivatives, an anti-aging composition and use of 4-n-furfurylcytosine and/or its derivatives in the manufacture of anti-aging composition
WO2011115513A2 (en) * 2010-03-19 2011-09-22 Instytut Chemii Bioorganicznej Pan A cytosine analogue, a method of preparation of a cytosine analogue, a dna methyltransferase 1 inhibitor, a method for dna methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal dna methylation
KR20160123677A (ko) * 2015-04-16 2016-10-26 플라스미아 바이오텍 에스엘 시토신 뉴클레오시드 유사체의 효소적 생산

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009349A2 (en) * 2003-07-22 2005-02-03 Supergen, Inc. Composition and method for treating neurological disorders
WO2009067035A2 (en) * 2007-11-25 2009-05-28 Instytut Chemii Bioorganicznej Pan Method of obtaining of 4-n-furfurylcytosine and/or its derivatives, an anti-aging composition and use of 4-n-furfurylcytosine and/or its derivatives in the manufacture of anti-aging composition
WO2011115513A2 (en) * 2010-03-19 2011-09-22 Instytut Chemii Bioorganicznej Pan A cytosine analogue, a method of preparation of a cytosine analogue, a dna methyltransferase 1 inhibitor, a method for dna methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal dna methylation
KR20160123677A (ko) * 2015-04-16 2016-10-26 플라스미아 바이오텍 에스엘 시토신 뉴클레오시드 유사체의 효소적 생산

Similar Documents

Publication Publication Date Title
MX2021004431A (es) Procesos novedosos.
JOP20220271A1 (ar) مركبات دايازينو بيريميدين كمثبطات لـ her2
CR20210563A (es) Compuestos y métodos para el tratamiento de covid-19
CY1123260T1 (el) Ενα αλας νατριου του ν-((1,2,3,5,6,7-eξaϋδpo-s-inδaken-4-υλ)καρβαμοϋλ)-1-ισοπροπυλ-1η-πυραζολο-3-σουλφοναμιδιου
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
NO20090321L (no) Anvendelse av substituerte 2-aminotyetraliner for produksjon av et medikament for forhindringen, lettingen og/eller behandlingen av diverse typer smerte
NO20080284L (no) Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
BR9814327A (pt) Compostos de tiouréia e benzamida, composições e pro-cessos para tratamento ou prevenção de doenças infla-matórias e arteriosclerose
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
EA202191239A1 (ru) Соединения и их применение для лечения дефицита 1-антитрипсина
BRPI0415753A (pt) método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm
MX2022011697A (es) Inhibidores de ciclofilina y usos de los mismos.
MX2022009285A (es) Inhibidores macrocíclicos de la quinasa rip2.
MX2025012370A (es) Compuesto de amida, composicion farmaceutica que comprende el compuesto y uso de esta
ECSP045397A (es) 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS
PH12022551094A1 (en) Novel insulin analogues and uses thereof
PL450139A1 (pl) 4-N-furfurylocytozyna i kompozycja ją zawierająca do zastosowań medycznych
MX2024003015A (es) Nuevos derivados de quinolina.
RU2007104774A (ru) Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы
PH12019502580A1 (en) Synergistic compositions comprising (r)-dimiracetam (1) and (s)-dimiracetam (2) in a non-racemic ratio
MX2022007175A (es) Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.
MX2024000239A (es) Medicamentos que comprenden inhibidores de la glicosidasa.
PL430116A1 (pl) Zastosowanie związku typu triterpenu lupanu do zapobiegania i leczenia choroby Alzheimera i kompozycja farmaceutyczna